
28 new research reports landed this week! Stockpick among analysts is Natco Pharma, with an estimated 44% upside according to Karvy. The company has seen a strong quarter on the back of sales of generic Tamiflu. Natco is manufacturing the first generic equivalent of Tamiflu now available in the US, where the drug saw around $403 million worth of annual sales in 2015. Flu season in the US is typically in the ongoing period of December-March, where a large % of Tamilflu sales occur.